(00:45)
 Could you just provide our listeners with a little bit of information about you and your background?
 
 (01:00)
 The laboratory recently made some updates to this testing for minimal residual disease. Can you just give us a brief overview of that assay?

(03:22)
 So these patients go through these treatments, and at what point do they really need this testing, or when should it be considered by clinicians to perform it?

(05:18)
 What brought the laboratory to flow cytometry for this MRD test for this particular disease state? Why did we not choose those other methods?

(09:44)
 So hearing you talk about how this test is serving the entire patient population, how are these results for this minimal residual disease test used for patient care?